A Breakthrough in Cardiac Surgery: Preventing Kidney Injury with SGLT2 Inhibition
Up to half of cardiac surgery patients face the risk of acute kidney injury (AKI), a concerning statistic that highlights the need for effective preventive measures. However, as Dr. Maartina Oosterom-Eijmael and her team from Amsterdam UMC Locatie AMC point out, current strategies are lacking. But here's where it gets interesting: previous trials have hinted at a potential solution.
During the American Society of Nephrology Kidney Week 2025, researchers presented a groundbreaking study titled "MERCURI-2: A Randomized Controlled Trial in People Undergoing Cardiac Surgery." This triple-blinded, placebo-controlled trial aimed to test whether a specific drug, dapagliflozin, could reduce postoperative AKI in cardiac surgery patients. The results were nothing short of remarkable.
The study focused on adult patients undergoing elective cardiac surgery. Participants were randomly assigned to receive either dapagliflozin (10 mg) or a matching placebo once daily, starting the day before surgery and continuing for two days post-surgery. The primary goal was to compare the incidence of AKI between the two groups, using the Kidney Disease: Improving Global Outcomes criteria.
In a comprehensive analysis of 784 patients between June 2023 and May 2025, the findings were clear: there was a significant reduction in AKI incidence in the dapagliflozin group compared to the placebo group (28% vs 53%). This translates to a substantial absolute difference of 25%, a statistic that speaks volumes about the drug's effectiveness.
Breaking down the results further, the dapagliflozin group saw 23% of patients diagnosed with AKI stage 1, 4% with stage 2, and a mere 0.8% with stage 3. In contrast, the placebo group had significantly higher numbers: 40% with stage 1, 13% with stage 2, and 0.3% with stage 3. These numbers highlight the drug's ability to not only reduce AKI incidence but also mitigate its severity.
The authors concluded that this large-scale, multicenter trial provides strong evidence that perioperative SGLT2 inhibition is a powerful tool in preventing AKI associated with cardiac surgery. This breakthrough has the potential to revolutionize postoperative care and improve patient outcomes.
And this is the part most people miss: the controversy. While the results are impressive, the interpretation of these findings and their potential impact on clinical practice is a topic of ongoing debate. Some experts argue that further research is needed to fully understand the long-term effects and potential risks associated with SGLT2 inhibition. Others believe that these findings should prompt an immediate shift in clinical guidelines. What do you think? Should we embrace this new treatment strategy, or do we need more evidence before implementing it on a wider scale? We'd love to hear your thoughts in the comments below!
